Results 71 to 80 of about 8,597,475 (170)

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 500-506, May/June 2026.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source

Attenuation of Oxygen‐Induced Neovascularization and Inflammation by Neutralizing VEGFA and/or ANG‐2 With an Antibody

Genes to Cells, Volume 31, Issue 3, May 2026.
The effects of intraocular administration of neutralizing antibodies against VEGFA, ANG‐2, or bispecific to these two factors on pathological findings were examined in the oxygen‐induced retinopathy (OIR) mouse model. The antibody to VEGFA or ANG‐2 attenuated oxygen‐induced neovascularization and inflammation, and the bispecific antibody more ...
Hirokazu Oohashi, Toshiro Iwagawa, Hiroto Abe, Chihiro Kawaji, Yuta Inokuchi, Tetsuhiro Soeda, Kosuke Saita, Makoto Aihara, Sumiko Watanabe   +8 more
wiley   +1 more source

Nanostructured drug delivery systems for posterior segment eye diseases: Strategies to defy ocular barriers

BMEMat, Volume 4, Issue 1, March 2026.
Efficient drug delivery to the posterior segment of the eye has long been a challenging issue due to the complex ocular barriers. The review focuses on the promise held by nanoplatforms for barrier penetration and the key mechanisms involved, also highlighting their advantages in achieving efficient drug delivery and superior treatment of PSEDs ...
Yifan Shen, Ying Yao, Yan Zhang, Xinyu Shi, Ling Bai, Yang Zhong, Yan Zhang, Kun Zhang   +7 more
wiley   +1 more source

Place of New Anti-Vascular Endothelial Growth Factor Agents in Recalcitrant Radiation Maculopathy: Case Reports

Case Reports in Ophthalmology
Introduction: Anti-vascular endothelial growth factor (VEGF) therapy is the main treatment alternative in radiation maculopathy as it reduces the macular edema and thereby improves the vision to some extent.
Özlem Ural Fatihoglu, Murat Tunc, Ali Osman Saatci   +2 more
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Aflibercept high-dose (8mg) related intraocular inflammation (IOI) – a case series

BMC Ophthalmology
Background Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg.
Laura Hoffmann, Stephan Michels, Chiara Eandi, Muntadher Al Karam, Eva C. de Oliveira Figueiredo, Katja Hatz   +5 more
doaj   +1 more source

Retinal vasculitis after intravitreal aflibercept 8 mg for neovascular age-related macular degeneration

Japanese Journal of Ophthalmology
Abstract Purpose To evaluate short-term outcomes of intravitreal injection of aflibercept 8 mg for neovascular age-related macular degeneration (nAMD). Study design Retrospective, interventional case series.
Hidetaka Matsumoto, Junki Hoshino, Saki Numaga, Kaori Mimura, Yosuke Asatori, Hideo Akiyama   +5 more
openaire   +2 more sources

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Background: Intravitreal aflibercept 8 mg could improve treatment outcomes and provide sustained disease control in patients with neovascular age-related macular degeneration (nAMD), with extended dosing compared with aflibercept 2 mg. Methods: PULSAR is
Eichenbaum D., Holz F. G., Clark W. L., Reed K., Schmelter T., Yancopoulos G. D., Lanzetta P., Chu K. W., Rao R., Leal S., Hirshberg B., Heier J. S., Sun W., Korobelnik J. -F., Cheng Y., Schmidt-Ott U., Bhore R., Wong T. Y., Berliner A. J., Schulze A., Xiaodong S., Iida T., Vitti R., Zhang X.   +23 more
core   +1 more source

Aflibercept 8 mg in neovascular age-related macular degeneration and diabetic macular oedema: Translating clinical trials into clinical practice

Provide expert-informed guidance on the integration of aflibercept 8 mg into routine clinical care for patients with neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO), based on clinical trial and real-world evidence ...
Taiji Sakamoto, Michael W. Stewart, Charles C. Wykoff, Frank G. Holz, Andreas Stahl, Anat Loewenstein, Sobha Sivaprasad, David Eichenbaum, Paolo Lanzetta, Chui Ming Gemmy Cheung, Jean-Francois Korobelnik, Richard Gale, Javier Zarranz-Ventura, Marion R. Munk, Varun Chaudhary, Tien Yin Wong   +15 more
core   +1 more source

Fellow-eye effect of intravitreal aflibercept 8mg in a patient with bilateral refractory nAMD: a case report and literature review

BMC Ophthalmology
Background Intravitreal anti–vascular endothelial growth factor (anti-VEGF) therapy remains first-line therapy for the treatment of neovascular age-related macular degeneration (nAMD), but the high frequency of injections imposes a substantial burden on ...
Jingfa Zhang, Fan Zhang, Ping Wang, Bo Lin, Mingming Yang, Qingshan Chen   +5 more
doaj   +1 more source